Leucine-based motif and clostridial neurotoxins
AssigneeAllergan, Inc.
InventorsLance E. Steward, Todd M. Herrington, Kei Roger Aoki
Life of this patent
Estimating the term…
Abstract
Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.
Claims2
A modified botulinum neurotoxin type E having increased biological half-life,
- wherein the modification comprises the addition of the leucine-based motif of SEQ ID NO:
- 3, and
- wherein the added leucine-based motif increases biological half-life of the modified botulinum toxin type E relative to an identical botulinum toxin type E without the added leucine-based motif.
Dependencies are inferred from the claim text.